Estimating Platelet Counts with ROTEM PLTEM in Laboring Women with Low Platelets or Heavy Bleeding

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, single-center, observational study conducted at Hospital General Universitario Gregorio Marañón in Madrid. It will measure PLTEM, calculated as EXTEM-A5 minus FIBTEM-A5, to see how well it reflects platelet count in obstetric patients with thrombocytopenia and/or severe postpartum hemorrhage. No interventions are performed; the study observes current clinical management and outcomes. The goal is to determine if PLTEM can serve as a rapid point-of-care tool to support neuraxial anesthesia decisions and transfusion strategies in obstetric emergencies.

Why it matters

Who can join: the full rules

Inclusion criteria:

* Parturients with a suspicion or confirmed thrombocytopenia before delivery (platelet count \< 120x10\^9/L),
* Parturients with severe postpartum haemorrhage (blood loss \>1500 mL) with a suspicion of thrombocytopenia.

Exclusion criteria:

* parturient age under 18 years;
* refusal to participate

Where it's running

• Hospital General Universitario Gregorio Marañón
  Madrid, Spain Recruiting

Study contacts

• Study coordinator: Nicolas Brogly, MD, PhD
• Email: nicolas.brogly@salud.madrid.org
• Phone: +34 663676820

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Predicting bleeding risk in patients with severe thrombocytopenia using a viscoelastic and clinical score

  We test a new score that combines viscoelastic test results with clinical data to see if we can predict bleeding risk in adults with malignant hematologic disorders and very low platelets.

  Recruiting Centre Hospitalier Annecy Genevois · Épagny, Auvergne-Rhône-Alpes · NCT07653672

• Etamsylate versus placebo to prevent bleeding after stem cell transplant

  This will test whether etamsylate can reduce bleeding in adults with very low platelets after hematopoietic stem cell transplantation.

  Recruiting Phase 3 First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang · NCT07442513

• Umbilical cord blood therapy for cancer treatment–related low platelets

  This trial will try an intravenous umbilical cord blood infusion to see if it raises platelet counts in people aged 12–65 with cancer treatment–induced thrombocytopenia.

  Recruiting Phase 2 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT07441720

• Herombopag for low platelets caused by T‑DM1 in breast cancer

  This will test whether herombopag tablets can raise or stabilize platelet counts in breast cancer patients who developed low platelets after T‑DM1 so they can continue planned T‑DM1 cycles.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07257809

• Umbilical cord blood-derived megakaryocyte injection for chemotherapy-related low platelets

  This single-dose treatment will try to raise platelet counts in adults with cancer who developed low platelets from anti-cancer therapy.

  Recruiting Phase 1 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07110090

• Using apixaban to treat blood clots in cancer patients with low platelet counts

  This study is testing if a new dose of the blood thinner apixaban can safely help cancer patients with low platelet counts manage blood clots without causing more bleeding.

  Recruiting Early Phase 1 Beth Israel Deaconess Medical Center · Boston, Massachusetts · NCT06886516

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.